Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMKNASDAQ:DWTXNASDAQ:KPRXNASDAQ:LSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMKDMK Pharmaceuticals$0.17$0.18▼$21.70$2.34M1.111.16 million shs24.16 million shsDWTXDogwood Therapeutics$4.65-10.2%$4.85$1.62▼$29.28$8.89M1.881.63 million shs51,671 shsKPRXKiora Pharmaceuticals$3.02-1.9%$3.07$2.51▼$5.55$9.19M-0.68134,036 shs35,752 shsLSBLakeshore Biopharma$0.95-4.1%$1.24$0.87▼$8.60$8.83M0.5921,032 shs19,167 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMKDMK Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DWTXDogwood Therapeutics+7.47%+5.93%+6.80%-15.36%+517,999,900.00%KPRXKiora Pharmaceuticals-2.53%-0.32%-3.45%-4.94%-37.40%LSBLakeshore Biopharma-0.01%-0.91%-14.67%-51.48%+98,989,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDMKDMK PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics2.0114 of 5 stars3.50.00.00.02.00.01.3KPRXKiora Pharmaceuticals3.1405 of 5 stars3.55.00.00.02.21.70.6LSBLakeshore Biopharma0.6345 of 5 stars0.03.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMKDMK Pharmaceuticals 0.00N/AN/AN/ADWTXDogwood Therapeutics 3.00Buy$10.00115.05% UpsideKPRXKiora Pharmaceuticals 3.00Buy$10.00231.13% UpsideLSBLakeshore Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DMK, KPRX, DWTX, and LSB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.003/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMKDMK Pharmaceuticals$3.62M0.00N/AN/A($0.38) per share0.00DWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/AKPRXKiora Pharmaceuticals$16M0.57N/AN/A$7.14 per share0.42LSBLakeshore Biopharma$672.27M0.01N/AN/A$8.86 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMKDMK Pharmaceuticals-$26.48MN/A0.00N/AN/A-630.85%N/A-251.02%N/ADWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%8/6/2025 (Estimated)KPRXKiora Pharmaceuticals-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%8/8/2025 (Estimated)LSBLakeshore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)Latest DMK, KPRX, DWTX, and LSB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/A3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMKDMK PharmaceuticalsN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ALSBLakeshore BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMKDMK PharmaceuticalsN/A0.580.54DWTXDogwood TherapeuticsN/A1.711.71KPRXKiora PharmaceuticalsN/A8.978.97LSBLakeshore Biopharma0.131.170.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMKDMK Pharmaceuticals38.55%DWTXDogwood Therapeutics9.05%KPRXKiora Pharmaceuticals76.97%LSBLakeshore Biopharma52.64%Insider OwnershipCompanyInsider OwnershipDMKDMK Pharmaceuticals5.90%DWTXDogwood Therapeutics3.90%KPRXKiora Pharmaceuticals0.05%LSBLakeshore BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMKDMK Pharmaceuticals1110.10 million9.51 millionNo DataDWTXDogwood Therapeutics51.91 million1.17 millionN/AKPRXKiora Pharmaceuticals103.04 million2.97 millionNot OptionableLSBLakeshore Biopharma7739.31 millionN/AN/ADMK, KPRX, DWTX, and LSB HeadlinesRecent News About These CompaniesHead to Head Comparison: Fulcrum Therapeutics (NASDAQ:FULC) versus Lakeshore Biopharma (NASDAQ:LSB)June 10 at 1:45 AM | americanbankingnews.comLakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)April 23, 2025 | prnewswire.comLSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27thFebruary 6, 2025 | businesswire.comLakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial ApprovalDecember 19, 2024 | markets.businessinsider.comLakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year GuidanceDecember 19, 2024 | prnewswire.comLakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 13, 2024 | finanznachrichten.deLakeShore Biopharma Faces Challenges Amid Criminal Probe into Former ChairmanDecember 12, 2024 | markets.businessinsider.comLakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 12, 2024 | globenewswire.comLakeShore Biopharma Co Ltd Ordinary SharesNovember 23, 2024 | morningstar.comLakeShore Biopharma Advances PIKA Rabies Vaccine ApprovalNovember 8, 2024 | markets.businessinsider.comLakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of PakistanNovember 8, 2024 | markets.businessinsider.comLakeShore Biopharma Announces Leadership TransitionNovember 2, 2024 | markets.businessinsider.comLakeShore Biopharma Achieves Nasdaq Compliance MilestoneOctober 29, 2024 | markets.businessinsider.comLakeShore Biopharma regains ompliance with Nasdaq minimum bid price requirementOctober 29, 2024 | markets.businessinsider.comLakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 29, 2024 | prnewswire.comLakeShore Biopharma Advances with Rabies Vaccine TrialOctober 26, 2024 | markets.businessinsider.comLakeShore’s YSJA rabies vaccine receives approval for Phase III trial in ChinaOctober 26, 2024 | markets.businessinsider.comLakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies VaccineOctober 25, 2024 | prnewswire.comLakeShore Biopharma Shares Higher on Unchanged FY GuidanceOctober 10, 2024 | marketwatch.comLakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial GuidanceOctober 8, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMK, KPRX, DWTX, and LSB Company DescriptionsDMK Pharmaceuticals NASDAQ:DMKDMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.Dogwood Therapeutics NASDAQ:DWTX$4.65 -0.53 (-10.23%) Closing price 04:00 PM EasternExtended Trading$4.67 +0.02 (+0.43%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Kiora Pharmaceuticals NASDAQ:KPRX$3.02 -0.06 (-1.95%) Closing price 04:00 PM EasternExtended Trading$3.07 +0.05 (+1.66%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Lakeshore Biopharma NASDAQ:LSB$0.95 -0.04 (-4.13%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
